Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.

{"article_title":"Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma.","author":"Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB, Ljungberg B, Marconi L, Merseburger AS, Volpe A, Abu-Ghanem Y, Dabestani S, Fern\u00e1ndez-Pello S, Hofmann F, Kuusk T, Tahbaz R, Bex A","journal_title":"European urology","issn":"1873-7560","isbn":"","publication_date":"2019-08-01","volume":"76","issue":"2","first_page":"151","page_count":"","accession_number":"31151678","doi":"10.1016\/j.eururo.2019.05.022","publisher":"Elsevier Science","doctype":"Journal Article","subjects":"Antineoplastic Combined Chemotherapy Protocols therapeutic use; Carcinoma, Renal Cell drug therapy; Kidney Neoplasms drug therapy; Antibodies, Monoclonal, Humanized administration & dosage; Antineoplastic Combined Chemotherapy Protocols adverse effects; Axitinib administration & dosage; Bevacizumab administration & dosage; Carcinoma, Renal Cell secondary; Humans; Ipilimumab administration & dosage; Kidney Neoplasms pathology; Nivolumab administration & dosage; Sunitinib therapeutic use","interest_area":["Urology & Nephrology"," Oncology"],"abstract":"Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. PATIENT SUMMARY: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment na\u00efve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria. Copyright \u00a9 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.","url":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&db=mdl&AN=31151678","isPdfLink":false,"isSAML":false,"an":"31151678","number_other":"","type_pub":"","issn_electronic":"1873-7560","languages":"English","language":"eng","date_entry":"Date Created: 20190602 Date Completed: 20201103 Latest Revision: 20201103","date_update":"20240105","titleSource":"European urology [Eur Urol] 2019 Aug; Vol. 76 (2), pp. 151-156.","date_pub_cy":"","type_document":"","contract_publisher":"","authored_on":"2019-08-01","description":"Recent randomised trials have demonstrated a survival benefit for a front-line ipilimumab and nivolumab combination therapy, and pembrolizumab and axitinib combination therapy in metastatic clear-cell renal cell carcinoma. The European Association of Urology Guidelines Panel has updated its recommendations based on these studies. PATIENT SUMMARY: Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve). This applies to all risk groups as determined by the International Metastatic Renal Cell Carcinoma Database Consortium criteria.<br \/> (Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.)","upload_link":"https:\/\/search.ebscohost.com\/login.aspx?direct=true&site=eds-live&scope=site&db=mdl&AN=31151678&authtype=shib&custid=ns346513&group=main&profile=eds","no_of_pages":"","authored_by":"Albiges L, Powles T, Staehler M, Bensalah K, Giles RH, Hora M, Kuczyk MA, Lam TB, Ljungberg B, Marconi L, Merseburger AS, Volpe A, Abu-Ghanem Y, Dabestani S, Fern\u00e1ndez-Pello S, Hofmann F, Kuusk T, Tahbaz R, Bex A"}